Paragon Bioservices awarded 2013 CMO Leadership Award for Quality and Reliability

NewsGuard 100/100 Score

Paragon Bioservices, a contract manufacturing organization whose expertise is the process development and manufacturing of biopharmaceuticals, announced today that it has been awarded the 2013 CMO Leadership Award for Quality and Reliability.

"We are very honored to receive this award from Life Science Leader -- especially because this is our third consecutive year," said Dr Marco Chacon, Paragon's CEO. "For more than twenty years, we have helped pharmaceutical and biotechnology companies and government agencies move forward in the development and manufacturing of vaccines (VLPs), monoclonal antibodies and therapeutic proteins. We've completed two expansions in the past 4 years in order to constantly improve these capabilities.  Therefore, customer service, quality and reliability truly are key areas of focus at Paragon Bioservices. The fact that we were recognized in the top 20% by more than 10,000 pharmaceutical executives is extremely gratifying to all of us at Paragon."

According to Jon Howland, Vice President of Publishing at Life Science Leader magazine, "These awards were conceived to better serve pharmaceutical and biopharmaceutical executives in their vetting process.  It gives them information on what their peers think of a wide range of CMOs and helps them to ultimately identify the leading CMOs in the industry."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Extended CPAP treatment boosts lung development in premature infants